A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Shares of cancer drug startup, whose investors include Carlyle Group and Temasek, are down 7% a week after their trading debut Key takeaways Four rounds of fundraising together with IPO…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
